Huabao pharmaceutical biology belongs to the pharmaceutical industry fund, which is a theme investment.
Industry funds mainly invest in specific industries, and pharmaceutical funds will make 8% of their assets into pharmaceutical stocks. The advantage lies in centralization, and the disadvantage lies in centralization. It belongs to a typical high-risk and high-return category. The ability to select stocks for fund managers is also relatively high. Since the establishment of the fund, the current performance is acceptable. At the same time, we can also pay attention to Huitianfu Pharmaceutical Fund, which has performed even better than Huabao Pharmaceutical in the last year or two.
The aging society in China will become more and more serious, and the huge demand is enough to support the performance of pharmaceutical companies. Moreover, medicine is an aperiodic industry with anti-inflation properties. There is no problem in the medium and long-term prospects of the industry. Appropriate participation is recommended. Relatively suitable for fixed investment, share some market risks through fixed investment. One-time purchase requires investors' risk tolerance, but due to the large increase in pharmaceutical funds last year, it is best to invest for more than 3 years, otherwise there may be short-term losses.
Chinese businessmen's theme selection suggests careful choice, and other companies can also change. Although this year is not bad, the fund manager is ok. However, the overall strength of China fund companies is average. Since the prosperity of Chinese businessmen in 20 10, there has been no outstanding performance, and even many products are poorly made. Moreover, there have been great changes in personnel recently. At present, the whole company feels unstable, which is the biggest worry.